Trump’s CDC Pick Faces Scrutiny Over Independence

Erica Schwartz, nominated by President Trump to lead the Centers for Disease Control and Prevention (CDC), faced intense questioning about her independence from Health Secretary Robert F. Kennedy Jr. during her confirmation hearing. Democrats and Republican committee chairman Bill Cassidy expressed frustration with Schwartz’s answers.

Schwartz’s predecessor, Susan Monarez, was ousted after challenging Kennedy’s vaccine agenda. Schwartz promised “radical transparency” and vowed not to “betray the science,” but she avoided specifying how she would respond to directives unsupported by scientific evidence.

Sen. Tim Kaine noted that Monarez once gave similar assurances, which led him to oppose her confirmation. Sen. Maggie Hassan asked whether Schwartz would comply with a hypothetical directive to halt a flu vaccine campaign amid an epidemic. Schwartz declined to address hypotheticals, prompting Hassan to counter that this situation had occurred previously under Kennedy’s orders.

Bill Cassidy expressed dissatisfaction, stating, “We need a CDC director who will stand up to erroneous statements undermining immunization.” Schwartz denied any vaccine-autism links but hesitated to remove related language from the CDC’s website. Shaughnessy Naughton of 314 Action criticized Schwartz’s performance, deeming it “deeply disappointing” and “disqualifying.”

In other policy discussions, Acting Attorney General Todd Blanche pledged to block the sale of abortion medication through mail, reflecting opposition to a Biden-era policy. Meanwhile, a significant increase in cyclosporiasis cases was reported, with the CDC investigating over 5,100 potential cases.

Additional news highlighted other health policy influences, such as legislation in California concerning abortion pill labels and declining ACA enrollments in Missouri. Syphilis rates in North Dakota soared by 309% over five years.